Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients
Status:
Terminated
Trial end date:
2021-10-06
Target enrollment:
Participant gender:
Summary
This phase II randomized study will assess the effect of receiving IV recombinant human IL-7
(CYT107) versus placebo in lymphopenic sepsis patients
The aim is to confirm the immune cell reconstitution observed in other studies and other
patient populations among which the IRIS-7 A&B study which was conducted in the same patient
population.
Phase:
Phase 2
Details
Lead Sponsor:
Revimmune
Collaborators:
George Clinical Pty Ltd University Hospital, Limoges Washington University School of Medicine